Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S, Scambia G, Villanucci A, Naglieri E, Ibarbia MA, Brusa F, Bourgeois H, Sorio R, Casado A, Reichert D, Dopchie C, De Rivas B, de Sande LM. Pignata S, et al. Among authors: reichert d. Oncologist. 2021 Apr;26(4):e658-e668. doi: 10.1002/onco.13630. Epub 2021 Jan 3. Oncologist. 2021. PMID: 33289956 Free PMC article. Clinical Trial.
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB, Reichert D, Ringsdorf U, Kuther M, Hesse T, Sehouli J, Wimberger P. Runnebaum IB, et al. Among authors: reichert d. J Cancer Res Clin Oncol. 2018 Jun;144(6):1185-1195. doi: 10.1007/s00432-018-2637-1. Epub 2018 Apr 6. J Cancer Res Clin Oncol. 2018. PMID: 29623421 Free PMC article.
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Kaufmann M, Maass N, Costa SD, Schneeweiss A, Loibl S, Sütterlin MW, Schrader I, Gerber B, Bauer W, Wiest W, Tomé O, Distelrath A, Hagen V, Kleine-Tebbe A, Ruckhaeberle E, Mehta K, von Minckwitz G; GBG-39 Trialists. Kaufmann M, et al. Eur J Cancer. 2010 Dec;46(18):3184-91. doi: 10.1016/j.ejca.2010.07.009. Epub 2010 Aug 24. Eur J Cancer. 2010. PMID: 20797843 Clinical Trial.
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer.
Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, Bergmann T, Göhler T, Welslau M, Große-Thie C, Guntinas-Lichius O, von der Grün J, Balermpas P, Orlowski K, Messinger D, Stenzel KG, Fietkau R. Hecht M, et al. Among authors: reichert d. BMC Cancer. 2020 Sep 29;20(1):933. doi: 10.1186/s12885-020-07440-w. BMC Cancer. 2020. PMID: 32993574 Free PMC article. Clinical Trial.
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich HD, Tesch H, Wohlfarth T, Eustermann H, Hinke A. Jackisch C, et al. Among authors: reichert d. BMC Cancer. 2014 Dec 8;14:924. doi: 10.1186/1471-2407-14-924. BMC Cancer. 2014. PMID: 25487774 Free PMC article.
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).
Thill M, Wimberger P, Grafe A, Klare P, Luedtke-Heckenkamp K, Reichert D, Zaiss M, Ziegler-Löhr K, Eckl T, Schneeweiss A. Thill M, et al. Among authors: reichert d. Breast Cancer Res Treat. 2022 Nov;196(2):311-321. doi: 10.1007/s10549-022-06710-4. Epub 2022 Sep 12. Breast Cancer Res Treat. 2022. PMID: 36094611 Free PMC article.
207 results